HAEM5:Volunteer Assignments and Opportunities: Difference between revisions

[unchecked revision][unchecked revision]
No edit summary
No edit summary
Line 1,776: Line 1,776:
|
|
|-
|-
|Primary large B-cell lymphoma of immune-privileged sites||Disease|| || || || || ||GC|| ||
|[[HAEM5:Primary large B-cell lymphoma of immune-privileged sites|Primary large B-cell lymphoma of immune-privileged sites]]||Disease|| || || || || ||GC|| ||
|
|
|Ashwini Yenamandra, PhD FACMG, Vanderbilt University Medical Center
|Ashwini Yenamandra, PhD FACMG, Vanderbilt University Medical Center
Line 1,783: Line 1,783:
|
|
|-
|-
|Primary cutaneous diffuse large B-cell lymphoma, leg type||Disease|| || || || || ||GC|| ||
|[[HAEM5:Primary cutaneous diffuse large B-cell lymphoma, leg type|Primary cutaneous diffuse large B-cell lymphoma, leg type]]||Disease|| || || || || ||GC|| ||
|
|
|
|
Line 1,790: Line 1,790:
|
|
|-
|-
|Intravascular large B-cell lymphoma||Disease|| || || || || ||GC|| ||
|[[HAEM5:Intravascular large B-cell lymphoma|Intravascular large B-cell lymphoma]]||Disease|| || || || || ||GC|| ||
|
|
|Kate Berry, MBBS, BBus (Hons), Pathology Queensland
|Kate Berry, MBBS, BBus (Hons), Pathology Queensland
Line 1,797: Line 1,797:
|
|
|-
|-
|Primary mediastinal large B-cell lymphoma||Disease|| || || || || ||GC|| ||
|[[HAEM5:Primary mediastinal large B-cell lymphoma|Primary mediastinal large B-cell lymphoma]]||Disease|| || || || || ||GC|| ||
|
|
|
|
Line 1,804: Line 1,804:
|
|
|-
|-
|Mediastinal grey zone lymphoma||Disease|| || || || || ||GC|| ||
|[[HAEM5:Mediastinal grey zone lymphoma|Mediastinal grey zone lymphoma]]||Disease|| || || || || ||GC|| ||
|
|
|
|
Line 1,811: Line 1,811:
|
|
|-
|-
|High-grade B-cell lymphoma, NOS||Disease|| || || || || ||GC|| ||
|[[HAEM5:High-grade B-cell lymphoma, NOS|High-grade B-cell lymphoma, NOS]]||Disease|| || || || || ||GC|| ||
|
|
|Aiko Otsubo, PhD, Indiana University
|Aiko Otsubo, PhD, Indiana University